The pCODR Expert Review Committee (pERC) has provisionally recommended the funding of nab-paclitaxel (Abraxane) with gemcitabine hydrochloride for patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas.  Funding should be for patients with a KPS of 100-70 (or ECOG PS 0-2) conditional on the cost-effectiveness being improved to an acceptable level.

For more details, go to: http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-abraxane-mpc-in-rec.pdf